Rasmus Holm-Jorgensen
Director of Finance/CFO at ACRIVON THERAPEUTICS, INC.
Net worth: 158 096 $ as of 2024-06-29
Rasmus Holm-Jorgensen active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Director of Finance/CFO | 2022-03-31 | - |
Career history of Rasmus Holm-Jorgensen
Former positions of Rasmus Holm-Jorgensen
| Companies | Position | Start | End |
|---|---|---|---|
| KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC | Founder | 2015-06-30 | 2022-03-31 |
| Corporate Officer/Principal | 2015-06-30 | 2022-03-31 | |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 2010-12-31 | 2014-12-31 |
Training of Rasmus Holm-Jorgensen
| University of Copenhagen | Graduate Degree |
Statistics
International
| United States | 4 |
| Denmark | 2 |
Operational
| Corporate Officer/Principal | 2 |
| Founder | 1 |
| Graduate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Kiniksa Pharmaceuticals Ltd.
 Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Kiniksa Pharmaceuticals International Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA. | Health Technology |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
